Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (16270)	9/14/2003 9:39:17 PM
From: Cacaito	Respond to of 17367

Acne case already argue, now the other Rap: Arthritis???? Why He even mentioned it, first time I heard ceoperson shooting with mouth full open, the interviewer should get Barbara Walters job!!! xoma sinking in Arthritis, please has the fda panel send the guy into delirious, the Rap got more arthritis proven with increasing dose, a liability, most in psoriasis subjects that did not have arthritis to begin with. xoma does make the case for SinkingInequities. I could tolerate that they think transplantation again (anything goes in that field anyway), when I saw the protocol the failure was there, all the current drugs plus Rap, vs all the current drugs, to tough to tackle. Yes, it is plausible to deal with it, but start out of the US, a protocol in subjects with not protocol cause there is no care and xoma will give it for free (Mexico, Africa, Brazil), but forget the US, they already failed. Maybe, a chance in the recent theory (back by case series) of heavy antirejection treatment early on and then stop everything (the case series is from subjects who abandon treatment and were found years to decades later, still going strong). Lupus? forget it, Rituxan is the drug for that one.